Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2009

01-09-2009 | Original Paper

Substantially reduced expression of PIAS1 is associated with colon cancer development

Authors: Domenico Coppola, Vevek Parikh, David Boulware, George Blanck

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2009

Login to get access

Abstract

Purpose

Protein inhibitors of activated STATs (PIAS) regulate the interferon-gamma (IFN-γ) signaling pathway, which has numerous effects on tumor development and tumor cell biology. PIAS’s also regulate STAT family members not directly involved in IFN-γ signaling. This project was designed to assess PIAS1 expression in colon cancer.

Methods

To determine whether PIAS1, one of the PIAS family members, or IFN-γ signaling pathway components could be used to stratify colon tumors, we stained tissue microarrays for PIAS1, interferon regulatory factor-1 (IRF-1) and STAT1α.

Results

PIAS1 staining of the colon cancer tissue microarrays indicated a strong correlation of normal colon cells, and adenomas, with high expression of both PIAS1 and IRF-1.

Conclusion

The PIAS1 results in particular may represent a basis for new approaches for efficiently distinguishing adenomas from colon cancer.
Literature
go back to reference Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A et al (2005) Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26:1527–1535. doi:10.1093/carcin/bgi113 PubMedCrossRef Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A et al (2005) Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26:1527–1535. doi:10.​1093/​carcin/​bgi113 PubMedCrossRef
go back to reference Eason DD, Blanck G (2001) High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. J Immunol 166:1041–1048PubMed Eason DD, Blanck G (2001) High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. J Immunol 166:1041–1048PubMed
go back to reference Guo W, Romano J (2007) A generalized Sidak-Holm procedure and control of generalized error rates under independence. Stat Appl Genet Mol Biol 6: (article 3) Guo W, Romano J (2007) A generalized Sidak-Holm procedure and control of generalized error rates under independence. Stat Appl Genet Mol Biol 6: (article 3)
go back to reference Klampfer L, Huang J, Swaby LA, Augenlicht L (2004) Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 279:30358–30368PubMedCrossRef Klampfer L, Huang J, Swaby LA, Augenlicht L (2004) Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 279:30358–30368PubMedCrossRef
go back to reference Luo XM, Ross AC (2005a) Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1. J Biol Chem 280:36228–36236. doi:10.1074/jbc.M505749200 PubMedCrossRef Luo XM, Ross AC (2005a) Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1. J Biol Chem 280:36228–36236. doi:10.​1074/​jbc.​M505749200 PubMedCrossRef
go back to reference Luo XM, Ross AC (2005b) Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1. J Biol Chem 280:36228–36236. doi:10.1074/jbc.M505749200 PubMedCrossRef Luo XM, Ross AC (2005b) Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1. J Biol Chem 280:36228–36236. doi:10.​1074/​jbc.​M505749200 PubMedCrossRef
go back to reference Ruiz-Ruiz C, Ruiz de Almodovar C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A (2004) The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem 279:19712–19720. doi:10.1074/jbc.M313023200 PubMedCrossRef Ruiz-Ruiz C, Ruiz de Almodovar C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A (2004) The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem 279:19712–19720. doi:10.​1074/​jbc.​M313023200 PubMedCrossRef
go back to reference Stempelj M, Kedinger M, Augenlicht L, Klampfer L (2007) Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate. J Biol Chem 282:9797–9804. doi:10.1074/jbc.M609426200 PubMedCrossRef Stempelj M, Kedinger M, Augenlicht L, Klampfer L (2007) Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate. J Biol Chem 282:9797–9804. doi:10.​1074/​jbc.​M609426200 PubMedCrossRef
go back to reference Tamura T, Ueda S, Yoshida M, Matsuzaki M, Mohri H, Okubo T (1996) Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 229:21–26. doi:10.1006/bbrc.1996.1752 PubMedCrossRef Tamura T, Ueda S, Yoshida M, Matsuzaki M, Mohri H, Okubo T (1996) Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 229:21–26. doi:10.​1006/​bbrc.​1996.​1752 PubMedCrossRef
go back to reference Xi H, Eason D, Ghosh D, Dovhey S, Wright K, Blanck G (1999) Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) Type IV promoter by interferon regulatory factors 1 and 2. Oncogene 18:5889–5903. doi:10.1038/sj.onc.1202969 PubMedCrossRef Xi H, Eason D, Ghosh D, Dovhey S, Wright K, Blanck G (1999) Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) Type IV promoter by interferon regulatory factors 1 and 2. Oncogene 18:5889–5903. doi:10.​1038/​sj.​onc.​1202969 PubMedCrossRef
Metadata
Title
Substantially reduced expression of PIAS1 is associated with colon cancer development
Authors
Domenico Coppola
Vevek Parikh
David Boulware
George Blanck
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0570-z

Other articles of this Issue 9/2009

Journal of Cancer Research and Clinical Oncology 9/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.